BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 990 filers reported holding BAXTER INTL INC in Q4 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $425,755 | -21.5% | 11,281 | -5.2% | 0.01% | -16.7% |
Q2 2023 | $542,339 | -51.6% | 11,904 | -56.9% | 0.01% | -57.1% |
Q1 2023 | $1,120,950 | +10.0% | 27,637 | +38.3% | 0.01% | 0.0% |
Q4 2022 | $1,018,910 | +115.4% | 19,990 | +127.5% | 0.01% | +100.0% |
Q3 2022 | $473,000 | +27.5% | 8,785 | +52.2% | 0.01% | +16.7% |
Q2 2022 | $371,000 | -18.8% | 5,773 | -2.5% | 0.01% | 0.0% |
Q1 2022 | $457,000 | +9.9% | 5,918 | +22.2% | 0.01% | 0.0% |
Q4 2021 | $416,000 | -8.2% | 4,844 | -14.3% | 0.01% | -25.0% |
Q3 2021 | $453,000 | +50.0% | 5,653 | +49.1% | 0.01% | +60.0% |
Q2 2021 | $302,000 | -5.6% | 3,792 | -0.5% | 0.01% | -28.6% |
Q1 2021 | $320,000 | +25.0% | 3,812 | +18.9% | 0.01% | +16.7% |
Q4 2020 | $256,000 | -74.8% | 3,207 | -74.6% | 0.01% | -62.5% |
Q3 2020 | $1,016,000 | +111.2% | 12,642 | +125.9% | 0.02% | +14.3% |
Q2 2020 | $481,000 | +21.8% | 5,597 | +14.8% | 0.01% | +16.7% |
Q1 2020 | $395,000 | +8.2% | 4,876 | +11.8% | 0.01% | +50.0% |
Q4 2019 | $365,000 | +17.7% | 4,360 | +23.3% | 0.01% | -38.5% |
Q3 2019 | $310,000 | +7.3% | 3,537 | +0.2% | 0.01% | 0.0% |
Q2 2019 | $289,000 | +1.0% | 3,529 | +0.2% | 0.01% | -13.3% |
Q1 2019 | $286,000 | +22.7% | 3,521 | +0.4% | 0.02% | -61.5% |
Q4 2018 | $233,000 | – | 3,506 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |